Navigation Links
Alvespimycin in Medical News

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

...osium). Kosan has expanded this Phase 1 trial to include the combination of alvespimycin plus trastuzumab and paclitaxel (Taxol(R)). In the first quarter 2008, Kosan plans to initiate a Phase 2 trial of alvespimycin as monotherapy in patients with HER2-positive metastatic breast cancer who ...

Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...
Alvespimycin in Medical Technology

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

...sion on Monday, June 2, 2008 at 8:00 am to 11 am CT. Abstract 2502, titled, "First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: alvespimycin (A) administered QOD or QD," will be presented at 8:00 to 8:15 am CT in room W375a by Keith Flaherty, M.D., of the University of Pennsylvania. About...

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer

...ients with HER2-positive metastatic breast cancer. alvespimycin has demonstrated the potential to disrupt the acti... to evaluate the safety and anticancer activity of alvespimycin as a single agent in patients who have not previou...ium demonstrated encouraging antitumor activity of alvespimycin in combination with trastuzumab (Herceptin(R)). ...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer. Epothilone...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

...ting in June Phase I Trial Expanding to Include alvespimycin Plus Trastuzumab Plus Pa.... We are expanding the Phase 1 trial to include an alvespimycin plus trastuzumab plus paclitaxel regimen to establ...his year. We believe that the clinical activity of alvespimycin seen in our breast cancer Phase 1 trials to date v...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

...combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

... initiation of our TIME registration program for tanespimycin in patients with multiple myeloma, and with plans underway to advance second- generation alvespimycin into later-stage trials in patients with HER2-positive metastatic breast cancer, we look forward to further characterizing the efficacy and safety pro...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

...apolis, IN, in a poster, titled, "Phase 1 Trial of alvespimycin (KOS-1022; 17-DMAG) and Trastuzumab," at the 2007 ...leadership in the Hsp90 inhibitor area." Phase 1 alvespimycin Results alvespimycin is a second-generation Hsp90 inhibitor that has de...
Alvespimycin in Biological Technology

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

... demonstrated potential activity. -- Kosan will withdraw Hsp90 inhibitor alvespimycin from development in order to commit resources to the development of ta...tabine(R)) and/or Herceptin(R). Kosan plans to discontinue development of alvespimycin in lieu of development of tanespimycin. The process of ending current alves...

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer. Epothilone...

Kosan Announces Third Quarter 2007 Financial Results

...e presentation of updated positive Phase 1 data on alvespimycin in HER2-positive metastatic breast cancer; Phase 1...a Phase 2 monotherapy trial of our Hsp90 inhibitor alvespimycin in newly-diagnosed patients with HER2-positive met...cal trial showing that Kosan's Hsp90 inhibitor alvespimycin demonstrated antitumor activity and tolerabili...

Kosan to Reacquire Epothilone Program From Roche

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan Biosciences to Host Research & Development Day on October 31, 2007

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhib...

Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...
Other Tags
(Date:8/28/2015)... ... 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients ... pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. , Dr. ... and then went on to earn his title of Doctor of Chiropractic from the ...
(Date:8/28/2015)... ... 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, was treated ... a good cause. In its second year, the “Music With A Mission” benefit concert ... The “Mission” of “Music With A Mission” is to raise money to help fund ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The newest ... not be available for general use any time soon, according to educational website Surviving ... biologic therapy that received orphan drug designation for mesothelioma last week from the FDA, ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... External Counterpulsation, ... Heart Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines with a ... Fit Clinic has been in business since 2007 helping people prevent and reverse ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked ... an exclusive ranking of the nation’s fastest-growing private companies. The list was unveiled online ... growth of 85% over the last three years, PREVENT ranks higher on the list ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
Other Contents